Roche

In the Tenaya and Lucerne studies, more than 60 per cent of Vabysmo patients could be treated every four months at two years. This…

Approval is based on results from the pivotal phase-I/II clinical study of Lunsumio

The approval marks Tecentriq’s sixth lung cancer indication in Europe

Approval based on interim Rainbowfish data which show pre-symptomatic babies treated with Evrysdi for at least one year were able…

The approval is based on pivotal data from the phase-III Polarix study, where Polivy plus R-CHP significantly improved…

Abevmy, co-developed by the two companies, is a biosimilar to Roche’s Avastin (Bevacizumab), and has been approved by Health…

The dose is administered as a single injection just under the skin in the thigh

The study evaluating Tiragolumab plus Tecentriq did not meet its co-primary endpoint of progression-free survival

If approved, Mosunetuzumab would be the first CD20xCD3 T-cell engaging bispecific antibody available to treat Follicular Lymphoma…

The treatment with Ocrevus resulted in a majority of patients experiencing no disease progression in a one-year analysis of…